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Understanding molecular interactions on immune cells is crucial for drug development 
to treat cancer and autoimmune diseases. When characterizing molecular interactions, 
the use of a relevant living model system is important, as processes such as receptor 
oligomerization and clustering can influence binding patterns. We developed a protocol 
to enable time-resolved analysis of ligand binding to receptors on living suspension cells. 
Different suspension cell lines and weakly adhering cells were tethered to Petri dishes 
with the help of a biomolecular anchor molecule, and antibody binding was analyzed 
using LigandTracer. The protocol and assay described in this report were used to char-
acterize interactions involving eight cell lines. Experiments were successfully conducted 
in three different laboratories, demonstrating the robustness of the protocol. For various 
antibodies, affinities and kinetic rate constants were obtained for binding to CD20 on 
both Daudi and Ramos B-cells, the T-cell co-receptor CD3 on Jurkat cells, and the 
Fcγ receptor CD32 on transfected HEK293 cells, respectively. Analyzing the binding 
of Rituximab to B-cells resulted in an affinity of 0.7–0.9 nM, which is similar to values 
reported previously for living B-cells. However, we observed a heterogeneous behavior 
for Rituximab interacting with B-cells, which to our knowledge has not been described 
previously. The understanding of complex interactions will be facilitated with the possi-
bility to characterize binding processes in real-time on living immune cells. This provides 
the chance to broaden the understanding of how binding kinetics relate to biological 
function.
Keywords: affinity, kinetics, therapeutic antibody, B-cells, t-cells, Cd20, Fcγ receptor
INtRodUCtIoN
The human immune system is a complex network of cells, which communicate with each other 
in a highly organized manner to defend the body from pathogens and other potentially harmful 
substances. One way in which immune cells communicate is through secreted molecules that bind 
to designated receptors on target cells. The recognition of a pathogen or another ligand by a cell-
surface receptor leads to an intracellular signaling cascade, which alters the immune cell’s behavior 
in response to the received stimulus. The effect triggered by a molecular interaction is not only 
dependent on the molecules engaged but is also affected by the affinity, avidity, and kinetics of the 
interaction.
A well-known example of this is the positive and negative selection of T-cells in the thymus; the 
fate of the thymocyte is dependent on how well the T-cell receptor binds self-antigens presented via 
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the MHC of antigen presenting cells. A high affinity interaction 
with self-antigens will lead to apoptosis, whereas a weak affinity 
will induce survival signals and promote positive selection (1). 
In this case, interactions of structurally very similar molecules 
can lead to completely opposing outcomes depending on the 
strength of the interaction. Therefore, a detailed characterization 
and quantification of a molecular interaction is required for an 
in-depth understanding of immune cells interacting patterns.
Apart from broadening our knowledge of physiological 
interactions, affinity and kinetics are also crucial when it comes 
to drug development (2). The fastest growing class of pharmaceu-
ticals is the one of monoclonal antibodies (mAbs) (3). The first 
approved mAb in 1986 was Muromonab, used for the treatment 
of renal graft rejection. Muromonab acts as an immunosuppres-
sor and binds to CD3, thereby inhibiting signaling and activation 
of T-cells (4). Since then, most of the developed mAbs have 
been for applications in oncology and autoimmunity (4). Their 
effects are partially mediated by the variable region binding to an 
epitope expressed on cancer cells and thus modifying the signal-
ing mediated via the receptor, usually resulting in growth arrest 
or apoptosis (5). However, it has become increasingly apparent 
over the last few decades that the clinical effectiveness of mAbs is 
also due to interaction with the immune system via the Fc part of 
the mAb. In a process termed antibody-dependent cell-mediated 
cytotoxicity, the Fc part of cell-bound mAbs is recognized by Fcγ 
receptors on NK cells, which ultimately leads to lysis of the tumor 
cell (6). In addition, complement-dependent cytotoxicity (CDC) 
is a suggested mechanism of action for mAbs (7) as shown for 
Rituximab (8).
Rituximab was approved by the FDA in 1997 as the first mAb 
for cancer therapy. It works by binding to the B-cell marker 
CD20 causing depletion of both malignant and normal B-cells 
(9). Due to its success in treating various B-cell malignancies 
(10, 11), second-generation anti-CD20 mAbs have been developed 
with improved properties (12, 13). For example, Ofatumumab, 
which is also an anti-CD20 mAb, exhibits an increased ability to 
induce CDC compared to Rituximab (14). It is thought that the 
redistribution of mAb-bound CD20 into lipid rafts plays a role in 
inducing CDC, and in an in vitro study, stronger CDC effects were 
correlated with slower off-rates of the tested mAbs (14). However, 
in a follow-up study these observations were challenged (15), 
and the role in which anti-CD20 off-rate contributes to lipid raft 
formation and CDC is debated (16, 17).
The effort to try and understand how kinetics relate to bio-
logical function is important, since this knowledge would help 
tailoring the design and selection of next generation mAbs (18). 
Due to the biological complexity of many interactions that are 
influenced by contributing co-receptors, receptor oligomeriza-
tion, and clustering, it is advantageous to measure interactions 
on the intended target cell type (19, 20).
There are many techniques available to study interactions 
between drugs and their targets (21) of which a number are 
suitable to not only study the affinity but also the kinetics. 
Some biophysical techniques, such as surface plasmon reso-
nance (SPR) (22), biolayer interferometry (BLI) (23), and the 
quartz crystal microbalance (QCM) (24), have been applied on 
interaction measurements where the target is in or on a cell. The 
measurement principle is either based on ligand binding induced 
changes in the refractive index in close proximity to a surface 
(SPR and BLI) or changes in the vibration frequency (QCM). 
A number of studies using living cells have been performed 
generating interesting correlations between ligand binding and 
overall cellular responses in a dose- and compound-dependent 
manner (25–27). To extract the interaction rate constants and 
the affinity from a real-time interaction measurement, however, 
the signal needs to be proportional to the number of bound 
complexes. A commonly used approach to minimize signals 
originating from density fluctuations of cells is to fixate them 
(28–31). With fixated cells, however, one risks missing the real-
life complexity of a living cell such as ligand binding induced 
clustering and dimerization of receptors (20, 32). Other aspects, 
such as sterical hindrance in antibody binding to the epidermal 
growth factor receptor 2 by mucins could be assessed (28). For 
interaction measurements on living cells, fluorescence-activated 
cell sorting (FACS) is commonly used, particularly in the area 
of immunology. Although FACS is mostly used for end-point 
assays, a number of studies reported dynamic interaction 
analysis by sampling from a larger reaction vessel at various time 
points (33, 34). As FACS is primarily designed for end-point 
measurements for cells in suspension, it lacks the possibility for 
rapid changing from ligand incubation to monitoring dissocia-
tion as removal of the ligand typically involves a centrifugation 
and suspension step. It also lacks simultaneous monitoring of 
non-specific interactions of the ligand to a reference area as 
commonly applied in instrumentation designed for real-time 
interaction analysis (35).
A method designed to measure ligand–receptor interactions in 
real-time on living cells is LigandTracer (36). From the resulting 
binding trace, kinetic parameters such as on- and off-rates and 
the affinity can be extracted. The shape of the binding trace also 
indicates if the interaction follows a simple “one-to-one” pattern, 
in which one ligand binds to one receptor in one defined way, or 
if the interaction is more complex. A prerequisite for the assay 
is that the cells stay attached in a confined area on the cell dish.
As reported by the literature, LigandTracer measurements 
have almost exclusively been conducted on adherent growing 
cells. A protocol based on EDC/NHS [1-ethyl-3-(3-dimethylami-
nopropyl)carbodiimide hydrochloride/N-hydroxysuccinimide] 
coupling for attachment of suspension cells has been applied 
(37, 38) but proved effective only in a few cases. In this study, we 
have developed a method that allows suspension cells to be teth-
ered in a confined area on a cell dish for a feasible measurement 
time of several hours, using a previously described biomolecular 
anchor molecule (BAM) for membranes (39, 40). Receptor–ligand 
interactions were successfully measured on four different cellular 
model systems with good reproducibility, and kinetic parameters 
quantifying the interactions could be estimated, opening up time-
resolved interaction measurements to living suspension cells.
MAteRIALs ANd Methods
Cell Culture
All cells were cultured in a humidified incubator at 37°C and 5% 
CO2. Three laboratories participated in the present study, so as to 
FIgURe 1 | (A) Workflow on how to adhere cells suitable for LigandTracer assays. Target and control cells are adhered in defined areas opposite each other on a 
Petri dish with the help of biomolecular anchor molecule (BAM). (B) Measurement principle of LigandTracer. The dish containing target and control cells is placed on 
an inclined and rotating support. A detector is mounted above the upper part of the dish. Cell medium with labeled ligand is added to the dish and due to the 
inclination of the dish remains in its lower part during the measurement. The fluorescence intensity from both target and control cells is measured once per rotation 
in the upper position.
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confirm the function of the protocol in different environments 
and in the hands of different operators.
In Sweden, K562, Jurkat, and SKOV3 cells were maintained 
in RPMI 1640 cell culture medium (Biochrom AG) supple-
mented with 10% FBS (Sigma Life Science), 1% l-glutamine 
and 1% penicillin–streptomycin (=PeSt) (both Biochrom 
AG). For Daudi cells in addition 1% sodium pyruvate (Sigma-
Aldrich) was added. A431 cells were maintained in Ham’s F10 
cell culture medium (Biochrom AG) supplemented with 10% 
FBS (Sigma Life Science) 1% l-glutamine and 1% PeSt (both 
Biochrom AG).
In the USA, Ramos (ATCC® CRL-1596™) cells were cultured 
in RPMI 1640 (ThermoFisher) supplemented with 10% FBS 
(Hyclone) and 1% PeSt (Gibco). HEK293 cells (used as negative 
control cells for experiments involving Ramos cells) were main-
tained in DMEM/F-12, HEPES (ThermoFisher) containing 10% 
FBS (ThermoFisher), 1% PeSt, 100  µg/ml Zeocin (Gibco), and 
400 µg/ml Geneticin (Gibco).
In the UK, HEK293 cells stably transfected with full length 
FcγRIIa (131  H 27Q allotype), and the parental HEK293 cells 
were cultured in DMEM (Sigma Life Science) containing 10% 
FBS (Sigma Life Science). For real-time interaction measure-
ments 1% PeSt (Sigma Life Science) was added.
Cell Attachment
Biomolecular anchor molecule (SUNBRIGHT® OE-040CS, 
NOF Corporation) was aliquoted as powder to avoid repeated 
freeze–thaw cycles and stored at −20°C in siliconized vials to 
prevent adsorption to the plastic. Directly before usage, BAM 
was dissolved in MQ to a concentration of 2 mg/ml. Two defined 
areas of a Petri dish (Nunc, Cat No 263991) were carefully 
covered with 400  µl of BAM solution by slowly pipetting the 
liquid onto the plate, so that a circular drop formed that was 
held in place by surface tension. The areas were about 1.5 cm 
in diameter and 5  mm from the rim of the dish on opposite 
positions (see Figure  1A). The prepared Petri dish was incu-
bated under sterile conditions at room temperature for 2 h. For 
cell seeding, cells were detached with trypsin when necessary, 
centrifuged at 700  rpm for 5  min, and resuspended in PBS 
to a concentration of 2.5 or 7.5 ×  106  cells/ml, depending on 
cell size. In detail, Daudi and Jurkat cells were resuspended to 
7.5 × 106 cells/ml, K562, SKOV3, A431, Ramos, and HEK293 
cells to 2.5  ×  106  cells/ml. We found that use of mechanical 
force while trypsinizing adherently growing cells had a nega-
tive impact on their subsequent attachment to the BAM coated 
dishes. Before adding the cell suspension, the remaining BAM 
solution was carefully aspirated from the dish, ensuring that the 
liquid did not exceed the defined area. Immediately after, 400 µl 
of cell suspension was added drop by drop onto each BAM 
coated spot and incubated at room temperature for 40 min. The 
dish was then tilted to remove the remaining suspension, and 
10 ml of complete cell culture medium was added before placing 
the dish in the incubator.
For control measurements on adherent growing cells, A431 
and SKOV3 cells were suspended to 0.33 × 106 cells/ml in com-
plete medium after trypsinizing, and 3  ml cell suspension was 
seeded at the lower part of inclined Nunc cell culture dishes. The 
dishes were kept inclined in the incubator to allow cell growth in 
a small portion of the dish only.
All dishes were incubated overnight in a humidified incubator 
at 37°C and 5% CO2 and used the following day for experiments.
Cell Viability
Viability of cells incubated on BAM over night was evaluated by 
completely removing the cell culture medium and adding 0.4% 
Trypan Blue (BioRad) diluted 1:1 in PBS for 2 min. Cells were 
washed once with PBS before images were taken with a phase 
contrast microscope (Nikon).
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Antibodies and Labeling
Antihuman CD32 (FcγRIIA) (BioXcell, Clone IV.3, Cat. 
No. BE0224), Cetuximab (Apoteket, Sweden), Trastuzumab 
(Apoteket, Sweden), as well as Rituximab (Apoteket, Sweden) 
used for experiments with Daudi cells were labeled with fluores-
cein isothiocyanate (FITC).
For labeling, FITC (Sigma-Aldrich) was dissolved in DMSO 
to 1 µg/µl. The antibody dissolved in PBS was diluted in double 
the volume of borate buffer pH 9, and 100  ng FITC was added 
per 1 µg antibody. The reaction was incubated at 37°C for 90 min, 
and labeled antibody was purified through an NAP-5 column 
(GE Healthcare). Labeled antibody was stored at −20°C until usage.
Rituximab (Invivogen, Cat. No. huCD20-Mab1) used for 
experiments involving Ramos cells was labeled with Alexa-fluor 
488 kit (Molecular Probes) according to the manufacturer’s 
instructions.
APC-labeled antihuman CD3 antibody was purchased from 
BioLegend (Cat. No. 300312).
Interaction Measurements with 
Ligandtracer
The interaction between labeled antibodies and living cells express-
ing a target receptor was measured in real-time with LigandTracer 
Green (Ridgeview Instruments). In this study, seven different 
LigandTracer Green instruments were used in three different 
laboratories.
For this assay, target cells are grown in a defined area of 
a Petri dish, which is placed on an inclined rotating support 
(see Figure 1B). The detection unit is mounted above the upper 
part of the dish. When adding medium containing fluorescently 
labeled ligand, the inclination ensures that the liquid is mainly in 
the lower part of the dish outside the detection area. During each 
full rotation, the signal from the target and a reference area is 
recorded. In this study, the reference area contained a negative cell 
line, i.e., cells that do not express the target receptor. The reference 
signal is automatically subtracted from the target signal, resulting 
in a real-time binding curve that represents specific binding of the 
labeled antibodies to target cells. For accurate kinetic interaction 
analysis, the number of receptors should remain stable throughout 
the experiment meaning that cells have to stay firmly attached.
Prior to kinetic measurements, the cell medium was replaced 
with 3 ml fresh medium. The dish was placed in LigandTracer 
Green equipped with either a Blue/Green or a Red/NIR detector 
depending on the fluorescent label used in the respective assay. 
All measurements were performed with 30 s detection time and 
5 s detection delay; this meant that the signal from each spot was 
measured for 30 s and that the signal was measured 5 s after the 
spot was placed in the detection area to allow the medium to 
drain from the cells. As each dish contains a target and a refer-
ence area opposite each other, a full rotation takes a little more 
than 70 s resulting in a data collection frequency of 0.9 min−1. A 
baseline signal was collected for 30 min, and then labeled ligand 
was added in two increasing concentrations. Each concentra-
tion was incubated until sufficient curvature was obtained for 
subsequent extraction of kinetic parameters. Dissociation of the 
ligand was recorded after replacing the incubation solution with 
3 ml fresh medium. Obtaining clear curvature during association 
measurements is crucial for robust data evaluation and is depend-
ent on the rate constants of the interaction, the concentration 
and incubation time. The concentrations of the antibodies in this 
study were chosen by the respective laboratory where the analysis 
was performed, so that visible curvature was obtained within a 
few hours of incubation time.
data Analysis
Binding traces were analyzed with the evaluation software 
TraceDrawer 1.7 (Ridgeview Instruments). Signal levels were nor-
malized to 0% at baseline level and 100% at the end of the second 
ligand incubation, respectively, to enable easy visual comparison 
of interaction traces. This is important as kinetic parameters are 
derived from the curve shape irrespectively of signal height. The 
normalized interaction curves were fitted to three kinetic interac-
tion models to obtain a census fit for all replicates. The use of a 
“one-to-one” model is the simplest approach and describes the 
binding of one type of ligand to one type of target.
This “one-to-one” or Langmuir binding model assumes that 
two types of molecules, such as a receptor (R) and a ligand (L), 
interact with each other in an identical and reversible manner. 
This means that the binding is fully characterized by the rate of 
complex formation, ka, the complex dissociation rate, kd, which 
depends on the stability of the complex, and the concentrations 
of the bound and free proteins:
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The equilibrium dissociation constant or affinity (KD) of 
the interaction is defined as the ratio between dissociation and 
association rate constants, kd/ka, and reflects the ligand concentra-
tion at which half of the receptors are occupied at equilibrium. 
In real-time interaction analysis, the rate constants are derived 
by monitoring a signal (B) that is proportional to the concentra-
tion of complexes [RL], while having a fixed number of receptors 
(Bmax). When incubating with a ligand concentration [L], the rate 
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and when the signal versus time curve contains enough curvature, 
the interaction rate constants (ka and kd) and Bmax can be derived.
The “one-to-two” model assumes that there are two types of 
target populations that the ligand binds to with different affinities. 
This model assumes that there are two simultaneous, independ-
ent “one-to-one” interactions. The “one-to-one two state” model 
represents a scenario where the ligand binds to one type of target 
and where the formed ligand-target complex undergoes a change 
to a different state from which the ligand cannot dissociate. This 
model assumes that the ligand-target complex can shift between 
the two states with distinct rate constants. A similar case to a “one-
to-one-two state” model is described by the “bivalent” model, in 
which it is assumed that the ligand has two possible binding sites 
and can bind to either one or both targets.
All antibody–receptor interactions were analyzed using the 
“one-to-one” model. Furthermore, the interaction between 
FITC-Rituximab and Daudi cells was fitted to the more complex 
FIgURe 2 | (A) Viability staining (Trypan Blue) of cells incubated on biomolecular anchor molecule overnight in an incubator. Dead cells are dark blue. (B) Cell spots, 
visible as round surface near the edge of a Petri dish with 10 cm diameter, before and after a 6 h LigandTracer assay with complete medium.
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kinetic models described above. To get an estimate of how 
reproducible the interaction measurements were, all replicates 
were fitted individually to extract the main contributing on- (ka) 
and off- (kd) rate and then average rate constants and affinities 
(=kd/ka) as well as standard deviations (SD) were calculated. 
If interaction curves have identical incubation times, the result 
from simultaneously fitting an interaction model to all presented 
curves according to a so-called global fit is presented in all figures.
ResULts
Reported values are presented as value (±SD) where applicable.
Cell Viability and Adherence
To verify that immune cells were viable on BAM after overnight 
incubation cells were stained with Trypan Blue. Representative 
images are shown in Figure 2A and illustrate that the majority of 
cells were viable. Adherence of cells was investigated by counting 
detached cells in the medium and imaging cell spots before and 
after a 6 h LigandTracer assay without ligand (Figure 2B). For 
Daudi and Jurkat cells, 0.6 (±0.3)% and 0.8 (±0.5)% of seeded cells 
were detached, respectively, whereas 11.3 (±4.3)% of K562 cells 
were found in the medium after a 6-h assay. Visual inspection of 
the cell layers confirmed that almost all cells stayed immobilized 
on the intended position on the cell dish.
Analysis of the Rituximab–Cd20 
Interaction on Living B-Cells
For analyzing the interaction between Rituximab and CD20, 
Daudi cells expressing high levels of CD20 were used as target 
cells whereas CD20 negative K562 cells served as control. After 
baseline acquisition, FITC-labeled Rituximab was added in two 
consecutive steps to final concentrations of 20 and 60 nM, fol-
lowed by dissociation measurement in fresh medium. Introducing 
fluorescence to the system resulted in an immediate initial signal 
increase for both target and control cells (Figure 3A). This was 
due to unbound fluorescent ligand in the thin liquid layer present 
on cells during signal detection. The signal for K562 cells rapidly 
stabilized at a low and constant level whereas a continuous signal 
increase was visible for Daudi cells resulting in a curve-shaped 
binding trace. This illustrates that FITC-Rituximab bound spe-
cifically to B-cells.
Repeated assays produced highly similar binding traces within 
an 8 h time frame (Figure 3B). The reference-subtracted inter-
action curves were fitted to different kinetic models to extract 
association rate constants (ka), dissociation rate constants (kd), 
tABLe 1 | overview of the kinetic parameters estimated for the indicated interactions by applying the indicated fitting models.
Interaction Fitting model ka (M−1 s−1 × 104) kd (s−1 × 10−5) Kd (affinity) (nM)
Rituximab–Daudi 1:1 1.4 (±7.6%) 1.3 (±5.2%) 0.9 (±6.6%)
Rituximab–Ramos 1:1 3.5 (±2.3%) 2.4 (±3.6%) 0.7 (±1.3%)
Rituximab–Daudi 1:2 1.6 (±9.9%) 0.3 (±22.3%) 0.2 (±18.6%)
Rituximab–Daudi 1:1, 2 state 1.6 (±10.0%) 28.6 (±10.2%) 1.0 (±3.2%)
Rituximab–Daudi Bivalent 0.9 (±5.9%) 7.3 (±6.7%) 7.8 (±5.9%)
Anti-CD3 mAb–Jurkat 1:1 8.7 (±15.0%) 4.4 (±13.4%) 0.5 (±5.4%)
Anti-CD32 mAb–HEK293_FcγRIIa 1:1 35.1 (±28.0%) 1.8 (±13.3%) 0.05 (±40.8%)
All values are presented as value (±SD).
FIgURe 3 | (A) Binding traces for fluorescein isothiocyanate (FITC)-Rituximab binding to Daudi cells (blue), K562 cells as CD20 negative control cells (black), and 
the subtracted trace: Daudi-K562 (red). (B) Binding traces for FITC-Rituximab binding to Daudi cells (n = 4, all reference subtracted with K562 as control cell line). 
Fluorescent signals were normalized to 0% at baseline level and 100% at the end of the second ligand incubation to facilitate visual comparison.
FIgURe 4 | Binding traces for fluorescein isothiocyanate-Rituximab binding to daudi cells (n = 4) (red) and curves resulting from globally fitting 
kinetic models (black). For all binding traces fluorescent signals were normalized to 0% at baseline level and 100% at the end of the second ligand incubation to 
facilitate visual comparison. (A) Fit from “one-to-one” model. (B) Fit from “one-to-one two state” model.
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and the affinities, also called equilibrium dissociation constant 
(KD) (Table 1). Fitting a “one-to-one” model to the interaction 
curves resulted in an apparent affinity of 0.9 nM (±6.6%) with an 
on-rate (ka) of 1.4 × 104 M−1 s−1 (±7.6%) and an off-rate (kd) of 
1.3 × 10−5 (±5.2%).
The “one-to-one” model assumes that one ligand binds to one 
target and is the simplest modeling approach for kinetic data. As 
can be seen in Figure 4A, the single dissociation rate, correspond-
ing to a single exponential signal decay, fitted to the data does 
not correspond well to the experimentally obtained dissociation 
pattern. Therefore, more complex models, such as the “one-to-
two” and “one-to-one two state” model, which assume that a 
second process contributes to the interaction, were fitted to the 
data. Applying the “one-to-two” model to the Rituximab–Daudi 
interaction curves resulted in an apparent affinity of 0.2  nM 
(±18.6%) for the dominating process. Fitting a “one-to-one two 
state” model to those binding curves gave an apparent affinity of 
1.0 nM (±3.6%). The resulting fit (black line) of the latter model 
is depicted in Figure  4B to exemplify that the more complex 
models correspond better to the measured data. The notion that 
Rituximab dissociation was not well described by a “one-to-one” 
model becomes apparent when looking at the initial 2 h of the dis-
sociation phase (corresponding to 2.5–4 h in Figure 4B) and the 
remainder of the dissociation phase (corresponding to 4.5–8 h 
FIgURe 5 | Binding traces of Alexa488–Rituximab binding to Ramos 
cells (red and blue) (n = 2, all reference subtracted with heK293 as 
control cells) and the calculated global fit according to a  
“one-to-one” model (black). Fluorescent signals were normalized to 0%  
at baseline level and 100% at the end of the second ligand incubation to 
facilitate visual comparison between binding traces.
FIgURe 6 | (A) Binding traces for fluorescein isothiocyanate (FITC)-Cetuximab binding to A431 cells intrinsically adhered on cell culture dishes (blue) and grown on 
biomolecular anchor molecule (BAM) (red) and the result from a global fit according to the “one-to-one” model (black). (B) Binding traces for FITC-Trastuzumab 
binding to SKOV3 cells intrinsically adhered on cell culture dishes (blue) and grown on BAM (red) and the result from a global fit according to the “one-to-one” model 
(black). For all binding traces, fluorescent signals were normalized to 0% at baseline level and 100% at the end of the second ligand incubation to facilitate visual 
comparison.
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in Figure 4B). Fitting a single exponential decay to the first 2 h 
of the dissociation phase resulted in an off-rate of 2.3 × 10−5 s−1 
(±17.0%), whereas a significantly slower off-rate of 7.4 × 10−6 s−1 
(±14.3%) was obtained for the remaining dissociation phase.
Since an antibody is a binder of bivalent nature, it has two 
potential binding sites that can recognize the same target epitope, 
which in turn may lead to a higher apparent affinity (41). 
Applying a “bivalent” model to the Rituximab–Daudi interac-
tion data resulted in an apparent affinity of 7.8 nM (±5.9%) for 
the initial binding step of Rituximab to CD20 molecule. This 
is approximately 10-fold lower binding strength than obtained 
for the same interaction analyzed according to the “one-to-one” 
model (Table 1), but analysis of the initial step alone leaves the 
avidity effect unquantified.
The interaction curves were more accurately described by the 
more complex models as reflected by a threefold lower chi-square 
value of the fit, suggesting that the process by which Rituximab 
bound to CD20 is more complex than a simple “one-to-one” 
mechanism. During data evaluation, it was noted that the “one-
to-one two state” model provided the most robust fitting results, 
although further systematic verification is needed to unravel the 
exact binding mechanism.
In a different laboratory, the interaction between Rituximab 
and CD20 expressed on Ramos cells was analyzed with two 
consecutive concentrations of 1 and 10 nM Alexa488–Rituximab 
(Figure 5) (Table 1). The obtained apparent affinity from a “one-
to-one” fit was 0.7 nM (±1.3%), which is similar to the apparent 
affinity observed for Rituximab binding to CD20 expressed on 
Daudi cells. The rate constants, however, are slightly faster for the 
interaction on Ramos cells (Table 1).
BAM does Not Influence  
Antibody–Receptor Interactions
To assess if adhering cells with BAM interferes with anti-
body–receptor interactions on living cells, interactions were 
measured using two adherent growing cell lines. Binding of 
FITC-Cetuximab and the binding of FITC-Trastuzumab to 
cells seeded on tissue culture plates was compared to cells 
adhered with BAM. Evaluating the interactions with a “one-
to-one” kinetic model resulted in an affinity of 0.02  nM for 
FITC-Cetuximab binding to EGFR on A431 cells in both cases 
(Figure  6A) (Table  2). FITC-Trastuzumab bound to HER2 
with an affinity of 0.21  nM on SKOV3 cells seeded in tissue 
culture plates and 0.18 nM on SKOV3 cells attached with BAM 
(Figure  6B) (Table  2). These results imply that tethering cells 
with BAM generated no significant differences for interaction 
analysis compared to the regular approach of seeding cells on 
tissue culture plates. For both antibody–cell interactions, the 
“one-to-one” binding model reflected the data well, therefore no 
other models were applied.
examples of Further Ligand–Immune 
Receptor Interactions
Further interactions between antibodies and different immune 
receptors were evaluated to demonstrate general applicability of 
tABLe 2 | Comparison of the kinetic parameters for interactions 
measured on intrinsically adhering cells versus cells tethered via 
biomolecular anchor molecule (BAM).
Interaction ka (M−1 s−1) kd (s−1) Kd (affinity) 
(nM)
Cetuximab–A431 adhered 1.3 × 105 2.7 × 10−6 0.02
Cetuximab–A431 BAM 1.4 × 105 2.4 × 10−6 0.02
Trastuzumab–SKOV3 adhered 5.7 × 104 1.2 × 10−5 0.21
Trastuzumab–SKOV3 BAM 6.2 × 104 1.1 × 10−5 0.18
All parameters were calculated by applying a “one-to-one” kinetic model.
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the assay setup. In order to analyze how a commercially avail-
able APC-labeled anti-CD3 antibody bound to the CD3 T-cell 
co-receptor, Jurkat cells were used as target and K562 cells as 
control. A “one-to-one” model was fitted to the resulting bind-
ing traces (Figure 7A), resulting in an average affinity of 0.5 nM 
(±5.4%) (Table 1).
HEK cells are commonly used as transfection hosts, but gen-
erally they do not adhere stably enough on regular cell culture 
dishes for a LigandTracer assay. Therefore, as a third example, 
HEK293 cells stably transfected with full length FcγRIIa, were 
used as target cells together with the parental cell line serving 
as a control. The binding of a commercially available anti-CD32 
antibody was fitted with a “one-to-one” model resulting in an 
affinity value of 0.04 nM (±40.8%) (Figure 7B; Table 1).
dIsCUssIoN
In this study, we describe and validate a method for enabling 
kinetic real-time measurements on living suspension cells in 
the time span of hours. We successfully followed ligand binding 
to four different suspension or weakly adhering cell lines in 
three different laboratories, demonstrating the robustness and 
general applicability of the method. The interaction between 
Rituximab and B-cells was analyzed in two different laboratories 
with different B-cell lines and different antibody concentrations 
and resulted in similar observed affinities of 0.7 and 0.9  nM. 
This further demonstrates the reproducibility of the presented 
protocol and the feasibility to transfer it to other laboratories. 
Immobilization of cells was achieved with the help of a BAM 
that has been described previously (39, 40). To ensure that BAM 
did not interfere with kinetic measurements, we used adher-
ently growing cell lines and verified that binding of mAbs did 
not change when cells were grown on BAM. In total, eight cell 
lines were stably adhered on Petri dishes using the presented 
protocol.
We observed that the tested cell lines stayed well attached 
during the measurements, which is a prerequisite for reliable 
measurements in Ligand Tracer. This is particularly true for slow 
dissociating ligands as cell detachment interferes with accurate 
measurement of the off-rate. We have shown, using Rituximab as 
an example, that we were able to measure binding and retention 
reproducibly for at least 8  h. Considering that many modern 
therapeutics are designed to have extremely slow off-rates, it is 
important to provide a relevant cell-based system that enables 
kinetic characterization of stable binders.
The immobilized cells tolerated the assay conditions well and 
stayed alive during measurements. However, we noted that more 
liquid accumulated over the cell area during signal detection than 
on a cell-free reference area of the dish. When a fluorescently 
labeled ligand is added to the dish, a bulk effect becomes notice-
able as an immediate upward jump in signal that stabilizes after 
a few minutes on a signal plateau. The reverse, i.e., a downward 
signal jump, is seen when the labeled ligand is removed during 
the dissociation phase. This behavior is different compared to 
adherent cell lines where a cell-free surface is generally suitable as 
reference area. To avoid confusion with fast binding processes, a 
negative control cell in the reference area is recommended for this 
suspension cell attachment protocol, especially when measuring 
fast interactions.
Measurements using living cells are desirable as epitopes 
can be changed upon chemical fixation, sometimes leading 
to decreased recognition by the binder. Fixation can result in 
FIgURe 7 | (A) Binding traces for APC anti-CD3 monoclonal antibody (mAb) binding to Jurkat cells (red, blue, and green) (n = 3, reference subtracted with K562 
cells) and the result from globally fitting all curves to a “one-to-one” model (black). (B) Binding traces for fluorescein isothiocyanate anti-CD32 mAb binding to 
HEK293 cells transfected with FcγIIa receptor (red and blue) (n = 2, reference subtracted with non-transfected HEK293 cells). As addition of the second 
concentration varies slightly in time, the results from fitting a “one-to-one” model to the individual curves are displayed (black). For all binding traces, fluorescent 
signals were normalized to 0% at baseline level and 100% at the end of the second ligand incubation to facilitate visual comparison.
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underestimation of the ligand’s binding strength or even com-
plete loss of binding to the target epitope. For example, Petrie 
et al. (42) described problems with a commercially available anti-
CD20 antibody after PFA fixation of cells. Fixation of cells also 
immobilizes the receptors in the cell membrane and thus prevents 
processes such as oligomerization and clustering of receptors. 
All these processes can contribute to the biological function of 
a receptor and can influence the kinetics of a ligand–receptor 
interaction. Therefore, measuring interaction process on living 
cells is important to decipher the underlying mechanism of a 
receptor–ligand interaction (32).
LigandTracer is designed to quantify molecular interactions 
on living cells and by tethering suspension cells to a Petri dish this 
method is extended for immunological applications. Compared 
to biophysical techniques for real-time interaction analysis, 
this method offers the advantage that ligand binding to living 
cells can be quantified rather than measuring cellular responses 
(26, 27, 43). Moreover, this method allows monitoring disso-
ciation processes slower than 1 × 10−5 s−1, which is considered 
the practical limit for SPR-based systems (44). As FACS can 
monitor multiple bound ligands to cells in suspension, it is 
ideally suited for multiplexed expression analysis. By sampling 
at various ligand incubation times, kinetic information can be 
extracted (45, 46). Repetitive sampling can be cumbersome, 
but as long as the interaction follows a “one-to-one” model, 
relatively few data points and only a partial dissociation phase 
are sufficient to extract the rate constants. When interaction 
processes are more complex, as observed for Rituximab bind-
ing to CD20, both the sampling rate and a full characterization 
of the dissociation phase as provided with the current method 
are beneficial.
We obtain an apparent affinity of about 1  nM for the 
Rituximab–CD20 interaction, which is close to values 
obtained by traditional saturation assays on living B-cells with 
Rituximab (4.4–5.5 nM) (47–49) and to values cited by the FDA 
(5.2–11 nM) (50). The affinities derived from cell-based assays 
are much higher than those obtained by biophysical systems 
like SPR on isolated proteins (160  nM) (51) or QCM on fix-
ated cells (650 nM) (52). The affinity of 0.18 nM obtained for 
Trastuzumab is similar to reported values independent of the 
technology [0.23 nM for ELISA (53), 0.13 nM for SPR (53)] or 
the fixation of cells [0.5–5.5  nM by SPR (28) and QCM (30), 
depending on cell line]. For Cetuximab, the affinity obtained 
by LigandTracer of 0.02 nM was very close to reported values 
on living cells (54, 55). Estimated affinity values from studies 
with fixated cells [0.53  nM for QCM (29) and 0.15  nM for 
ELISA (56)] and isolated protein systems [0.2 nM for SPR (56)], 
however, are about 10-fold weaker. Nevertheless, affinity values 
for Cetuximab and Trastuzumab obtained on living cells do 
not differ as much from measurements on non-living material 
as they do for Rituximab. One potential explanation for the 
relatively large difference is that, in contrast to Cetuximab and 
Trastuzumab, the Rituximab–CD20 interaction does not seem 
to follow a simple “one-to-one” interaction model but is better 
described by a heterogenous binding pattern, whose underlying 
cause might only be present in a living system.
The heterogenous behavior is evident when looking at the 
dissociation, where a significantly faster off-rate was observed 
during the initial 2 h of the dissociation phase compared to the 
remaining part. If the heterogeneous Rituximab–CD20 interac-
tion is evaluated with a “one-to-two” model, we obtain two affin-
ity values; 0.2 nM for the stronger interaction and 16 nM for the 
weaker one. Since manual assays generally do not have sufficient 
resolution to distinguish between several contributing processes, 
they will report only one affinity value. In the case of Rituximab 
binding to living B-cells, the reported value for traditional assays 
lies in between the high and low affinity contribution that we 
measure.
There are various reasons for an interaction to become 
hetero geneous. One possibility is that the heterogeneity reflects 
the bivalent nature of an antibody. Since an antibody has two 
potential binding sites toward its target, the fast and slow part of 
the dissociation could be due to an antibody population bound 
with only one arm versus a population bound with both arms. 
Internalization is another process that can cause heterogeneity. It 
should be noted however, that with similar systems like Cetuximab 
binding to A431 cells overexpressing EGFR or Trastuzumab 
binding to SKOV3 cells expressing high levels of HER2, the bind-
ing curves are well described by a “one-to-one” model meaning 
that the measured binding process is not significantly affected 
by other processes. Heterogeneous binding patterns can also be 
due to a more complex biology of a ligand–receptor interaction. 
The Rituximab–CD20 interaction can, for example, be stabilized 
by interacting with a second target such as an Fcγ receptor or 
through Fc–Fc interactions. It has been suggested that slow 
off-rates for anti-CD20 mAbs correlate with enhanced lipid raft 
formation and CDC (14, 57), although this observation remains 
controversial and is not yet fully understood (16, 17). It is yet to be 
investigated whether the formation of lipid rafts stabilizes bound 
Rituximab or if there is another underlying cause for the complex 
kinetic behavior of Rituximab.
There are a plethora of different suspension cell lines, which 
are an essential part of the immune system, and in addition, 
many types of cells of various origins that are weakly adherent. 
With our successful results from different suspension cells and 
HEK cells, as conducted by different operators in different labs, 
we show that the reported findings are consistent and transfer-
able. As not all immune cells are easily cultured ex vivo, it is of 
importance to use common transfection hosts, such as HEK 
cells when needed. The assay time of several hours was suitable 
to analyze modern therapeutics such as mAbs, which often 
display a slow dissociation rate. The cellular environment is 
important to study the real-life complexity of molecular inter-
actions that involve cell-surface receptors. As one example, 
the interaction between Rituximab and CD20 was analyzed 
on living B-cells, and we could see that the binding pattern of 
Rituximab was heterogeneous and more complex than what is 
reflected by a “one-to-one” model, which has not been reported 
previously. In conclusion, the method presented here provides 
the chance to broaden the understanding of molecular interac-
tions on a wider range of cell types, particularly within the field 
of immunology.
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